Tam-Peli Extends Survival to 13.3 Months in Relapsed Small-Cell Lung Cancer
Tam-Peli extends median survival to 13.3 months in relapsed small-cell lung cancer, a significant improvement over topotecan in phase...
Ivonescimab Cuts Death Risk 27% vs Pembrolizumab in NSCLC Trial
Ivonescimab cuts death risk 27% versus pembrolizumab in Phase III NSCLC trial, with median OS of 30.8 months versus...
Amivantamab plus chemotherapy achieves 34.3-month OS in EGFR exon 20 insertion lung cancer
Amivantamab plus chemotherapy achieves 34.3-month median overall survival in EGFR exon 20 insertion lung cancer, doubling historical survival rates.
Mitapivat Just Rewrote the Treatment Floor for Transfusion-Dependent Thalassaemia, Here’s What the ENERGIZE-T Data Actually Mean
ENERGIZE-T's Phase 3 data shows mitapivat cut transfusion burden in 258 thalassaemia patients. Here's what the trial design reveals...
CMO Location Drives Site Selection for Parkinsonian Imaging Trial
CMO location drives site selection for Parkinsonian imaging trial, requiring geographic proximity to manufacturing over patient populations.
J&J Exits LAA Closure Market, Sells Laminar Program to Jaguar LAA
Johnson & Johnson sells Laminar program to newly formed Jaguar LAA for left atrial appendage closure technology development and...
Iza-bren 2.5 mg/kg dose advances to Phase 3 in EGFR-mutated NSCLC
Iza-bren 2.5 mg/kg dose advances to Phase 3 in EGFR-mutated NSCLC after demonstrating superior efficacy and manageable safety in...
Tam-Peli meets primary endpoint for relapsed small-cell lung cancer in phase III trial
Tam-Peli meets primary endpoint for relapsed small-cell lung cancer in phase III trial, showing OS benefit over topotecan in...
What FDA’s July 2026 Psychedelic Drug Guidance Actually Says About Trial Design
FDA's finalized psychedelic guidance rewrites the rules on blinding, informed consent, and session monitoring, and the NEJM's September 2026...
Ennov Appoints Dr. Oxana Pickeral as New Chief Executive Officer
Ennov appoints Dr. Oxana Pickeral as Chief Executive Officer, succeeding 27-year founder Olivier Pâris amid accelerating regulatory compliance demand.